BREAST BRACHYTHERAPY OUTCOMES EVALUATION Margaret Pierce DNP, APRN, BC University of Tennessee Knoxville, Tennessee.

Slides:



Advertisements
Similar presentations
Mammary ductal carcinoma
Advertisements

Baptist Health System General Surgery Residency Program
Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center.
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.
Breast Cancer in Pregnancy
An update for Illinois Nurses Elizabeth A. Peralta, MD The Breast Center at SIU Springfield, IL May 2011.
Modified Megestrol The Clinical Trials by : Carolina R. Akib
Giuliano Pre-SSO mins ASCO Z mins
San Antonio Breast Cancer Symposium 2007 Highlights – Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford.
Breast Reconstruction: Outcomes Analysis Michael J Bass, MD, JD Michael J Bass Plastic Surgery, PLLC.
Julie R. Gralow, M.D. Director, Breast Medical Oncology, Seattle Cancer Care Alliance Professor, Medical Oncology, University of Washington School of Medicine.
Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.
AJCC TNM Staging 7th Edition Breast Case #3
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.
Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.
Intra-Operative Radiation Therapy for Treatment of Early Stage Breast Cancer: Short Term Results from a Single Institution Clinical Trial Using Electronic.
Partial Breast Irradiation Carol Marquez, M.D. Associate Professor, Department of Radiation Medicine Oregon Health and Sciences University.
Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.
Surgery Journal Club By : Ahmad Zahmatkesh Mohammadreza Nazemian.
Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.
Photodynamic Therapy for breast cancer
Breast Cancer Treatments and their Impact on Quality of Life Kim Arias.
Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2013 – December 31, 2013 Compiled by Uzma Nazim, M.D.
Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
Learn More At: CyberKnife Radiosurgery in the Treatment of Early and Advanced (Oligo-Metastases) Breast Cancer Sandra Vermeulen,
Breast Cancer By: Christen Scott.
Targeted Intraoperative Radiotherapy versus Whole Breast Radiotherapy for Breast Cancer (TARGIT-A Trial): An International, Prospective, Randomised, Non-Inferiority.
TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,
Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.
New York University Department of Radiation Oncology Prospective Randomized Trial of Prone Accelerated Intensity Modulated Whole Breast Radiation Therapy.
Effect of 21-Gene Reverse- Transcriptase Polymerase Chain Reaction Assay on Treatment Recommendations in Patients with Lymph Node-Positive and Estrogen.
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2009 – December 31, 2009.
Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2011 – December 31, 2011 Compiled by Lynn Day, RN BSN CCM CCRP.
Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2012 – December 31, 2012 Compiled by Uzma Nazim, M.D.
Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and.
Mamoun A. Rahman Surgical SHO Mr Osborne’s team. Introduction Blood transfusion: -Preoperative ( elective) -Intra/postoperative ( urgent) Blood transfusion.
Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2010 – December 31, 2010 Compiled by Lynn Day, RN BSN CCM CCRP.
Extranodal Extension on Sentinel Lymph Node Dissection: Why Should We Treat It Differently? Audrey Choi MD, Matthew Surrusco MD, Samuel Rodriguez MD, Khaled.
General Instructions for CRF 3 Rev H To be completed at each follow up visit Patient Identification and Group Date of Visit Assessment performed physician.
Basis and Outcome of Axillary Dissection for Node Negative Axilla Gurpreet Singh Dept. Of Surgery P.G.I.M.E.R. These Power Point presentations are free.
Treatment Options for Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Ongoing Studies This program is supported by an educational.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.
The impact of age on outcome in early-stage breast cancer 방사선종양학과 R2. 최진현.
Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Harvard Medical School Date 06/01/2007.
Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial Patricia.
PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,
Breast Cancer Treatment. Treatment 2 aspects 1. Treatment of the breast itself: “Local Treatment” 2. Treatment of the whole body = “Systemic treatment”
Breast Surgery in Delhi Breast Cancer Epidemiology Halsted Theory Radical Mastectomy Fisher Theory Modified Radical Mastectomy Goals of Breast Conservation.
THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.
Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.
Prognosis of younger patients in non-small cell lung cancer
Thanh Nhan Hospital MALE BREAST CANCER: CASE REPORT
Treatment Overview: The Multidisciplinary Team
Stamatia Destounis, MD, FACR, FSBI, FAIUM
C11 Breast cancer Treatments
Obesity Affects DIEP Flap Outcomes and Donor Site Complications
Presentation transcript:

BREAST BRACHYTHERAPY OUTCOMES EVALUATION Margaret Pierce DNP, APRN, BC University of Tennessee Knoxville, Tennessee

Background 178,000 women diagnosed with breast cancer in US in % localized to breast (stage T1, T2) Treatment options include: –Mastectomy –Partial mastectomy with whole breast irradiation –Partial mastectomy with brachytherapy

50% choose mastectomy

50% choose partial mastectomy with whole breast irradiation

Whole Breast Irradiation 5-7 weeks of daily treatments Disease-free survival is significantly improved with completion of therapy 25% do not complete course of radiation

Background Tumor bed most common site of recurrence Led to efforts to target therapy to surgical site –Limit radiation side effects? –No increased risk of recurrence

Interstitial catheters

Balloon Brachytherapy Placement of balloon catheter before treatment with radioactive seed placement twice daily for 5 days. Localized irradiation

innovation.freedomblogging.com/files/2007/10/

Literature Review Initial studies- survival and cosmetic outcomes comparable to whole breast irradiation. Identification of variables affecting outcomes other than tumor size, cell type and grade has been limited

Literature Review Most studies published in medical journals –Focused on disease recurrence rates, complication rates, and MD-judged cosmesis No nursing studies

Research Questions For women selecting breast brachytherapy –What are most frequent complications? –What are the relationships of subject characteristics to treatment outcomes? –What are the relationships of tumor characteristics to treatment outcomes? –What are the relationships of treatment variables to outcomes?

Method Retrospective case series study Medical records of subjects presenting for breast brachytherapy within the first year of treatment availability at study center

Subject Characteristics –N= 65, all Caucasian –Age years, mean age- 62 –BMI 20-49, mean –Breast size- 70% A, B, or C; 30% ≥ D –Post-menopausal 58 (90%) –HTN 32 (50%) –OA 21 (32%) –DM 13 (20%

Tumor Characteristics 92% T1, 8% T2 75% IDC Grade –46% 1 –26% 2 –26% 3 75% ER/PR+ Quadrant –52% UOQ –19% UIQ –13% LOQ –10% LIQ –6% Subareolar

Therapy-related Characteristics Margins –58% ≤ 2mm –42% ≥ 2mm Re-resection –26% Chemotherapy –61% endocrine –21% anthracycline –23 % other Surgery to catheter placement –Range 0-60 days –Mean/median 21.7/21 days Catheter in place (days) –Range 6-13 –Mean/median 8.6/9

Results Disease recurrence –None at F/U (12-18 months) Cosmesis –Excellent/Good 47/56 (84%) As noted by MD –Not documented for 9 subjects –Few records included patient perception

Results: Complications ComplicationN% Infection710.8 Chronic Pain812.3 Seroma Rad. Recall57.7 Fibrosis69.2

Results: Personal Characteristics and Outcome * p<.05, ** p<.01 Chronic painFibrosisInfectionCosmesis Age **(-) ** Menopause Status (-) ** DM RA

Results: Tumor Characteristics and Outcome * p<.05, ** p<.01 RecallErythemaPainInfectionFibrosisCosmesis Grade** ER(-)** PR(-)**

Results: Treatment Characteristics and Outcomes * p<.05, ** p<.01 SeromaHematomaChronic pain RecallCosmesis Re- resection ** (-)** Node dissection ** Anthracy- cline ** Time:Surg to catheter ** Time:Cath in place **

Conclusions Outcomes of recurrence, cosmesis, seroma and infection similar rates as previously published studies. Re-resection was associated with seroma, chronic pain, and poorer cosmetic outcome. Younger age and re-resection were associated with fibrosis. Axillary node dissection was associated with infection, fibrosis and pain. Initial data suggests good to excellent cosmetic outcomes and disease control.

Conclusions (cont.) Women with radiation recall reactions may be at greater risk for infection and seroma. Older women were more likely to report pain and drainage from catheter site after therapy. Recall reactions occurred in 5 of 14 subjects receiving anthracycline therapy. Menopausal status was negatively associated with erythema and fibrosis.

Limitations Incomplete documentation of cosmetic and complications in medical records made outcome evaluation incomplete. Small sample size. Number of variables to consider in analysis large for data set size. Patient satisfaction documented in only 37% of subjects.

Implications for Research Prospective study with standard data collection tool. Follow this cohort for long-term outcomes. Comparative analysis of outcomes with other therapies. Sexuality effects of treatment Qualitative studies- –Decision-making re: treatment options. –Women’s perceptions of outcomes.

Implications for Practice Minimize catheter time Prophylactic Abx Anthracycline Rx?- more aggressive prophylaxis & monitoring Promote early detection Ensure education re: treatment options